MHSPC
Clinical trials for MHSPC explained in plain language.
Never miss a new study
Get alerted when new MHSPC trials appear
Sign up with your email to follow new studies for MHSPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets advanced prostate cancer in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called LC-K76 combined with standard hormone therapy in 40 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and see if the drug helps lower PSA levels. Participants will take the drug for 24 weeks and …
Matched conditions: MHSPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
New hope for prostate cancer: Lower-Dose chemo combo shows promise
Disease control Not yet recruitingThis study is for men with metastatic hormone-sensitive prostate cancer (mHSPC) that has spread. It tests a combination of darolutamide, hormone therapy (ADT), and a lower dose of the chemotherapy drug docetaxel. The goal is to see if this approach can make PSA levels undetectabl…
Matched conditions: MHSPC
Phase: PHASE2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New test may predict prostate cancer treatment outcomes
Knowledge-focused Not yet recruitingThis study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will follow 50 newly diagnosed patients to see how their genetic features affect treatment resp…
Matched conditions: MHSPC
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated May 01, 2026 15:57 UTC